Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Intangibles (2021 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of Intangibles data on record, last reported at $231.9 million in Q3 2025.

  • For Q3 2025, Intangibles fell 9.34% year-over-year to $231.9 million; the TTM value through Sep 2025 reached $231.9 million, down 9.34%, while the annual FY2023 figure was $252.9 million, N/A changed from the prior year.
  • Intangibles reached $231.9 million in Q3 2025 per MIRM's latest filing, down from $237.9 million in the prior quarter.
  • Across five years, Intangibles topped out at $257.4 million in Q1 2024 and bottomed at $18.5 million in Q1 2022.
  • Average Intangibles over 5 years is $150.0 million, with a median of $231.9 million recorded in 2025.
  • Peak YoY movement for Intangibles: skyrocketed 346.21% in 2024, then dropped 9.34% in 2025.
  • A 5-year view of Intangibles shows it stood at $18.7 million in 2021, then decreased by 1.38% to $18.5 million in 2022, then surged by 1268.57% to $252.9 million in 2023, then increased by 1.13% to $255.8 million in 2024, then decreased by 9.34% to $231.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Intangibles were $231.9 million in Q3 2025, $237.9 million in Q2 2025, and $255.8 million in Q3 2024.